Number of Participants in the DRSP/E2 Group With an Assessment of Endometrial Hyperplasia or Worse at End of Study (EoS) (1 Year of Treatment) Up to one year [clinicaltrials_resource:8e90a1a8cda763033131e435a313de80]
The number of women who had a biopsy classified as 'hyperplasia or worse' at any time during the study. According to the protocol this endpoint was defined as primary for the DRSP/E2 group only.
clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]
Number of Participants in the DRSP/E2 Group With an Assessment of Endometrial Hyperplasia or Worse at End of Study (EoS) (1 Year of Treatment) Up to one year [clinicaltrials_resource:8e90a1a8cda763033131e435a313de80]
The number of women who had a biopsy classified as 'hyperplasia or worse' at any time during the study. According to the protocol this endpoint was defined as primary for the DRSP/E2 group only.
Bio2RDF identifier
8e90a1a8cda763033131e435a313de80
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:8e90a1a8cda763033131e435a313de80
measure [clinicaltrials_vocabulary:measure]
Number of Participants in the ...... dy (EoS) (1 Year of Treatment)
time frame [clinicaltrials_vocabulary:time-frame]
Up to one year
description
The number of women who had a ...... ry for the DRSP/E2 group only.
identifier
clinicaltrials_resource:8e90a1a8cda763033131e435a313de80
title
Number of Participants in the ...... r of Treatment) Up to one year
@en
type
label
Number of Participants in the ...... 0a1a8cda763033131e435a313de80]
@en